GAPDHP21

Across TCGA pan-cancer cohorts, GAPDHP21 RNA is linked to patient survival in 20 of 34 cancer types, making it the most broadly survival-associated GAPDHP21 data layer.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher GAPDHP21 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated GAPDHP21 expression acts as an unfavorable survival marker, although some lineages such as UCS and ESCA show a favorable association.

STAD, MESO, and UCS are the cancer types where GAPDHP21 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	DFS	Median	II,III,IV	0.470	0.595	.013	48	view →
MESO	OS	Tertile	IV	0.363	0.770	.005	47	view →
UCS	OS	Median	IV	0.817	0.302	.002	40	view →
LUAD	OS	Median	III,IV	0.517	0.803	.001	29	view →
SARC	DFS	Tertile	All	0.407	0.589	.003	27	view →
ESCA	OS	Quartile	All	1.000	0.158	.003	15	view →
KIRP	DFS	Median	IV	0.041	0.621	.019	15	view →
ACC	DFS	Tertile	All	0.458	0.749	.012	15	view →
KICH	DFS	Quartile	II,III,IV	0.379	1.000	.009	14	view →
LIHC	DFS	Median	III,IV	0.112	0.380	.004	13	view →
THYM	DFS	Tertile	III,IV	1.000	0.527	.031	10	view →
READ	OS	Quartile	IV	0.516	0.924	.030	8	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 20 lineages.

GAPDHP21–STAD (DFS)

Open the STAD breakdown →